Bladder Cancer
Cell Genesys launches expanded multiple-dose Phase 1 trial of CG0070 in recurrent bladder cancer
Published in Gene Therapy Weekly, August 17th, 2006
The expanded trial was prompted by encouraging interim safety and efficacy data recently reported for single-dose administration of CG0070 and will include up to 45 additional patients who have failed previous therapy with Bacillus Calmette-Guerin (BCG), the current standard therapy for recurrent bladder cancer.
CG0070, an oncolytic virus therapy that is being developed through a global alliance with Novartis AG, has been...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2006-08-17)
More Articles from Gene Therapy Weekly
- Cancer Gene Therapy
Survivin downregulation enhances melanoma cell sensitivity to cisplatin - Cancer Gene Therapy
Telomerase-selective oncolytic adenoviral agent enhances antitumor efficacy - Gene Research
Late gene mutants of bacteriophage lambda are an efficient expression vector - RNA Interference
Measles virus and subacute sclerosing panencephalitis virus inhibited by RNA interference - Stem Cell Research
Stem cell factor fused with erythropoietin mimetic peptide expressed in Escherichia coli - Adenovirus Pathogenesis
Adenovirus type 2 and type 5 E1A genes are expressed at different levels - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
